Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Taking a Look Back at Trials From ASCO GI 2022

February 1st 2022, 2:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Reviewing some of the most talked about abstracts that were presented at the 2022 Gastrointestinal Cancers Symposium.

Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer

January 31st 2022, 10:42pm

SGO Winter Meeting

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Increasing Rate of High-Risk Endometrial Cancer in Black Women Prompts Questions Into Underlying Causes

January 30th 2022, 11:00am

SGO Winter Meeting

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Minimally Invasive Surgery Could Benefit Patients with Advanced Ovarian Cancer

January 28th 2022, 10:07pm

SGO Winter Meeting

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical Cancer

January 28th 2022, 9:28pm

SGO Winter Meeting

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Immunotherapy Shakes Up Cervical Cancer Treatment Paradigm

January 28th 2022, 6:40pm

SGO Winter Meeting

Yovanni Casablanca, MD, discusses the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches

January 27th 2022, 10:20pm

SGO Winter Meeting

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.

TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors

January 23rd 2022, 11:00am

Gastrointestinal Cancers Symposium (ASCO GI)

The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

January 23rd 2022, 12:05am

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

Trastuzumab Deruxtecan Demonstrates Sustained Efficacy in HER2+ mCRC

January 22nd 2022, 8:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.

Nivolumab/Encorafenib/Cetuximab Triplet Elicits High Response Rate in MSS, BRAF V600E-Mutant mCRC

January 22nd 2022, 7:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC

January 22nd 2022, 6:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

Pembrolizumab Triplet Induces Deep, Durable Responses in Some Patients With Treatment-Refractory mCRC

January 22nd 2022, 6:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.

Onvansertib Plus FOLFIRI/Bevacizumab Generates Meaningful Responses in KRAS-Mutant mCRC

January 22nd 2022, 5:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.

Frontline Lenvatinib/TACE Improves OS in Advanced HCC

January 22nd 2022, 5:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

Transarterial chemoembolization plus lenvatinib led to a significant improvement in overall survival vs lenvatinib alone as frontline therapy in patients with advanced hepatocellular carcinoma, according to findings from the phase 3 LAUNCH trial.

Dr. Oh on the Results of the TOPAZ-1 Trial in Advanced Biliary Tract Cancer

January 22nd 2022, 3:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Dr. Hong on the Efficiency of the CodeBreaK 101 Trial in KRAS G12C-Mutated CRC and Other Solid Tumors

January 22nd 2022, 3:54pm

Gastrointestinal Cancers Symposium (ASCO GI)

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.

Dr. Bekaii-Saab on the Updated Results of the KRYSTAL-1 Trial in KRAS G12C+ GI Cancers

January 22nd 2022, 3:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

Pembrolizumab/Chemo Combo Emerges as Standard of Care in Esophageal Cancer/GEJ Adenocarcinoma

January 21st 2022, 10:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.

Dr. Abrams on the Rationale for the COSMIC-021 Trial in MSS/pMMR CRC

January 21st 2022, 10:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer.